Is Absci Corporation (ABSI) a Buy, Sell, or Hold?
Absci Corporation
NASDAQ:ABSI
$9.76 USD
-$0.47 (-4.59%)
- Volume
- 3.4M
- Average Volume
- 6.1M
- Market Capitalization
- $1.65B
- P/E Ratio
- -11.76
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $12.06
- Year Low
- $2.24
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.59
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Sean McClain |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ABSI |
| CUSIP | 00091E109 |
| CIK | 0001672688 |
| Web | https://www.absci.com |
| Phone | 360 949 1041 |
| Currency | USD |
| Employees | 140 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.59 |
| Quick Ratio | 6.59 |
| Cash Ratio | 0.43 |
Sales & Book Value
| Annual Sales | $2.8M |
| Price / Sales | 900.51 |
| Cash Flow | -0.64 |
| Price / Cash Flow | -16.78 |
| Price / Book | 8.68 |
Price Target and Rating
| Average Stock Price Forecast | $12.00 |
| High Stock Price Forecast | $16.00 |
| Low Stock Price Forecast | $9.00 |
| Forecast Upside/Downside | -18.67% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.84 |
| Trailing P/E Ratio | -11.76 |
| PEG Ratio | -1.15 |
| P/E Growth | -1.15 |
| Net Income | $-115.18M |
| Net Margin | -6450.76% |
| Pretax Margin | -6445.81% |
| Return on Equity | -63.58% |
| Return on Assets | -60.55% |
Financials Score
| AltmanZ Score | 37.95 |
| Piotroski Score | 4.00 |
| Working Capital | 111.94M |
| Total Assets | 195.59M |
| Ebit | -118.23M |
| Market Cap | 1.73B |
| Total Liabilities | 23.62M |
Poll Results
About Absci Corporation (NASDAQ:ABSI) Stock
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington. ...
2026-07-14 16:05:00
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026.
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
2026-07-13 10:55:25
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
2026-07-02 13:01:05
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
2026-06-25 11:26:10
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
2026-06-25 07:20:51
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
2026-06-24 09:09:12
Absci Corporation (NASDAQ:ABSI) stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program.
2026-06-24 06:35:00
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
2026-06-24 06:30:00
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts
Frequently Asked Questions
-
What is the current Absci Corporation (ABSI) stock price?
-
Absci Corporation(NASDAQ:ABSI) stock price is $9.76 in the last trading session. During the trading session, ABSI stock reached the peak price of $12.055 while $2.24 was the lowest point it dropped to. The percentage change in ABSI stock occurred in the recent session was --4.59% while the dollar amount for the price change in ABSI stock was -$-0.47.
-
ABSI's industry and sector of operation?
-
The NASDAQ listed ABSI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ABSI?
-
Sean McClain | Founder, Chief Executive Officer, President & Director
Amer-Denis Akkad | Vice President of Research
Amir Shanehsazzadeh | Chief AI Officer
Shelby Walker | Chief Legal Officer
Christine Lemke | Senior Vice President of Portfolio & Growth Strategy -
How many employees does ABSI have?
-
Number of ABSI employees currently stands at 140. ABSI operates from 18105 SE Mill Plain Boulevard, Vancouver, WA 98683, US.
-
Link for ABSI official website?
-
Official Website of ABSI is: https://www.absci.com
-
How do I contact ABSI?
-
ABSI could be contacted at phone #360 949 1041 and can also be accessed through its website. ABSI operates from 18105 SE Mill Plain Boulevard, Vancouver, WA 98683, US.
-
How many shares of ABSI are traded daily?
-
The average number of ABSI shares traded daily for last 3 months was 6.1M.
-
What is the market cap of ABSI currently?
-
The market value of ABSI currently stands at $1.65B with its latest stock price at $9.76